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Context:Hypercalcemia is reported as a rare finding in adrenal insufficiency, but is not well described
in congenital adrenal hyperplasia (CAH).
Methods: A retrospective chart review was conducted of patients with CAH diagnosed before the age of
2 years who had at least one recorded serum calcium measurement. Data from birth to 6 years of age
were reviewed.
Results: Of the 40 patients who met inclusion criteria, 33 (82.5%) had at least one elevated calcium con-
centration and 21 (53%) had two or more elevated calcium concentrations. Of the 126 elevated serum calcium
concentrations, themedianwas10.9mg/dL (range, 10.6 to 14.2mg/dL).Medianageat the last elevated calcium
measurement was 5 months (range, 0.3 to 46 months). Serum calcium concentration was inversely related to
age (r =20.124; P = 0.004). Overall, calcium level positively correlated with 17-hydroxyprogesterone (17OHP)
concentration (r = 0.170; P = 0.003), and this remained significant after adjusting for age (P, 0.05). However,
patients had hypercalcemia with both high and low 17OHP concentrations. Serum calcium concentration also
waspositively related to glucocorticoid (r=0.196;P=0.012) and fludrocortisone (r=0.229;P=0.003) doses, and
remained significant after age adjustment. Only seven patientswere evaluated for hypercalciuria. Of these, six
hadat least oneperiod of documentedhypercalciuria. Three patients hadnephrocalcinosis on renal ultrasound.
Conclusion: Children with CAH are at risk for developing hypercalcemia, hypercalciuria, and
nephrocalcinosis. Further studies are needed to determine the broader prevalence and the etiology of
hypercalcemia in CAH.
Copyright © 2017 Endocrine Society
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nd/4.0/).
Freeform/Key Words: congenital adrenal hyperplasia, adrenal insufficiency, hypercalcemia,
hypercalciuria, nephrocalcinosis
Congenital adrenal hyperplasia (CAH) describes a group of rare, autosomal recessive disorders of
impaired cortisol synthesis. Approximately 95% of CAH occurs becausemutations in theCYP21A2
gene, in turn, cause reduced 21-hydroxylase enzymatic activity and impaired adrenal cortisol
production [1]. These defects ultimately lead to increased adrenal androgen synthesis and female
virilization. Infantswith the classic formofCAHcanalsohavemineralocorticoiddeficiencyandmay
present with a life-threatening, salt-wasting crisis and hypovolemia. Hyponatremia and hyper-
kalemia are typically seen at presentation or during adrenal crises and resolve with treatment.
Abbreviations: 17OHP, 17-hydroxyprogesterone; AI, adrenal insufficiency; CAH, congenital adrenal hyperplasia.
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Hypercalcemia is relatively uncommon in children but can have serious clinical conse-
quences, including development of nephrocalcinosis and acute kidney injury [2]. Adrenal
insufficiency (AI) is a rare cause of hypercalcemia, although themechanism for hypercalcemia
is uncertain and a number of case reports describe resolution of hypercalcemia after steroid
replacement [3–8]. The most common cause of AI in infancy is CAH [9]. We have observed the
anecdotal occurrence of hypercalcemia in children with CAH; however, its prevalence has not
been established. To our knowledge, only one study reported classic CAH as a cause of hy-
percalcemia in two children [2] and no studies describe hypercalciuria or nephrocalcinosis.
The aim of this study was to determine the prevalence of hypercalcemia, hypercalciuria,
and nephrocalcinosis among infants and young children with CAH at our tertiary children’s
hospital. We also sought to explore the pathogenesis of these comorbidities in CAH.
1. Subjects and Methods
This retrospective cohort study was approved by the Indiana University School of Medicine In-
stitutional ReviewBoard. Patient records atRileyHospital forChildren, a tertiary care hospital in
Indianapolis, Indiana, were reviewed for all patients who were billed by the endocrine section
using the InternationalClassificationofDiseases,NinthRevision, code foradrenogenital disorders
(255.2) from January 1994 to March 2014. Patients were included in the study if they were di-
agnosedwithCAHbefore the age of 2 years.Datawere extracted frompatient recordsup to6years
of age based on observations of high calcium concentrations only during this time. Patients were
excluded after initial chart review if they did not haveCAH, if they hadnonclassic CAH, if they did
not have any records in thehospital system from the first 2 years of life, if they did not have at least
one calciummeasurement documented, and if their recordswere completely unavailable. Because
our hospital is a national referral center for genitoplasty procedures, somepatientswithCAHonly
had data available from their hospitalization for surgery and were excluded.
Recorded data included sex, race, CAH subtype (salt wasting or simple virilizing), age at
diagnosis of CAH, height, weight, body surface area, medications and doses, clinical labo-
ratory testing [i.e., basic metabolic profile and blood concentrations of calcium, phosphorus,
alkaline phosphorus, vitamin D, parathyroid hormone, 17-hydroxyprogesterone (17OHP),
androstenedione, and testosterone; plasma renin activity; and urine concentrations of cal-
cium and creatinine], and renal imaging studies, if available. Other comorbidities, such as
documented hypertension, were also recorded. Hypercalcemia was defined as serum calcium
concentration .10.5 mg/dL (.2.63 mmol/L), and hypercalciuria was defined according to
published normative data for children based on age [10].
The values of 17OHP and age were logarithmically transformed (log10) for analysis. The
relationships between variableswere tested using Pearson correlations and linear regression.
This was adjusted for age and for multiple measurements in individual subjects. Statistical
significance was set at P , 0.05. Analysis used SPSS statistics version 24 (IBM).
2. Results
A diagnosis code search identified 248 patients having the International Classification of
Diseases, Ninth Revision code 255.2 from January 1994 through March 2014 who were
evaluated by a pediatric endocrinologist at Riley Hospital for Children or at a satellite clinic.
Of these, paper or electronic records were unavailable for 35 patients. An additional 173
patient charts were reviewed and excluded, leaving 40 patients whomet the inclusion criteria
(Fig 1). The largest groups excluded comprised infants with classic CAH seen at our in-
stitution for genitoplasty only (not followed longitudinally) and patients who were found not
to have CAH based on chart review.
Patient characteristics are outlined in Table 1. Most patients were white (73%) or Hispanic
(23%). All patients were diagnosed with classic (i.e., 21-hydroxylase deficiency) CAH based on
clinical presentation. Genetic testing results were available to confirm the diagnosis of 21-
hydroxylase deficiency in eight patients. Most (90%) were reported to have salt-wasting CAH
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in their clinical records. Thirty-three patients (82.5%) had at least one elevated serum calcium
concentration. Of those, 12 had only one elevated serum calcium measurement recorded and
the remaining 21 had more than one recorded high serum calcium level. For patients with
calcium assessments, serum calcium was measured a median of 13 times (range, 1 to 48)
during the first 6 years of life, most often as part of a standard basic metabolic profile either
with routine screening laboratories or during hospitalization. Of the 126 elevated calcium
measurements, themedian calcium concentrationwas 10.9mg/dL (2.73mmol/L) with a range
of 10.6 to 14.2 mg/dL (2.65 to 3.55 mmol/L). Median age at the last elevated calcium con-
centration was 5months (range, 0.3 to 46months). Overall, serum calcium concentration was
inversely related to age (r = 20.124; P = 0.004).
Figure 1. Flow diagram of patient selection. ICD9, International Classification of Diseases,
Ninth Revision; NCCAH, nonclassic congenital adrenal hyperplasia.
Table 1. Patient Characteristics
All Patients Hypercalcemia Hypercalciuria Nephrocalcinosis
No. (% of total) 40 (100) 33 (84) 6 (15) 3 (8)a
Male sex, % 50 52 50 100
Salt-wasting CAH subtype, % 90 91 83 100
aTwelve of the total of 40 patients had at least one renal ultrasound assessment.
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Patients were being treated with glucocorticoids at the time of measurement in 83% of the
instances of hypercalcemia and with mineralocorticoid in 79%. The median 17OHP con-
centration was 2775 ng/dL (84 nmol/L) with range of 35 to 229,000 ng/dL at the time of
hypercalcemia. As seen in Fig 2, there was a slight positive correlation between the 17OHP
concentration and simultaneous serum calcium concentration (r = 0.170; P = 0.003), which
decreased but remained significant after adjusting for age (r = 0.132; P, 0.05). However, the
patient with the highest serum calcium level had hypercalcemia both with very elevated
[8201 ng/dL (248 nmol/L)] and very low [41 ng/dL (1.2 nmol/L)] 17OHP concentration [calcium
concentrations of of 12.4 and 14.2 mg/dL (3.1 and 3.6 mmol/L), respectively]. In addition, the
patient with very low serum calcium [6.9 mg/dL (1.7 mmol/L)] had elevated 17OHP con-
centration [12,300 ng/dL (373 nmol/L)].
Serum calcium concentration also was positively related to doses of glucocorticoid (r =
0.196; P = 0.012) and fludrocortisone (r = 0.229; P = 0.003). After age adjustment, calcium
concentration remained significantly related to glucocorticoid (r = 0.185; P = 0.018) and
fludrocortisone (r = 0.204; P = 0.009) doses.
Urine calciumwas assessed only in seven patients (Table 2). Of these, at least one period of
hypercalciuriawas documented by urine calcium to creatinine ratio on a randomurine sample
in six patients. Parathyroid hormonewasmeasured in only five of the 40 patients, all of whom
had hypercalciuria, and ranged from undetectable (with a simultaneous calcium concen-
tration of 13.9 mg/dL) to 46 pg/mL (with a simultaneous normal calcium concentration of
10.4 mg/dL). Vitamin D levels measured in three patients ranged from 29 to 43.9 ng/mL. Two
of these patients had hypercalciuria, and one had normal serum calcium measurements but
demonstrated poor growth. Four patients (12%) with hypercalcemia also had hypertension.
Twelve patients had renal ultrasound scans performed. Of those, three (25%) had documented
nephrocalcinosis, all of whom had hypertension. One patient had hypertension with a normal
renal ultrasound. Two patients had transient mild elevations in creatinine at the time of
diagnosis of CAH associated with hypercalcemia. However, no patient developed chronic
kidney failure. Details of the patients with hypercalciuria and/or nephrocalcinosis are out-
lined in Table 2.
Other than intravenous fluids for admitted patients, along with appropriate glucocorticoid
and mineralocorticoid treatment, patients did not undergo specific medical treatment of
Figure 2. Comparison of 304 simultaneous measurements of 17OHP (log-scale) and serum
calcium concentrations. Multiple data points are plotted for each patient (range, 0 to 25 per
patient). Normal calcium range is highlighted in the gray box. There was a positive
correlation (r = 0.170; P = 0.003), which remained significant after adjusting for age (r =
0.132; P = 0.024). To convert calcium mg/dL to mmol/L, multiply by 0.25. To convert 17OHP
ng/dL to nmol/L, multiply by 0.0303.
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hypercalcemia. No patient received bisphosphonates or calcitonin. One patient (patient 2 in
Table 2) started a low-calcium diet but remained hypercalcemic at the end of the study period.
3. Discussion
In this study, most children ,6 years of age with CAH had at least one episode of hyper-
calcemia and approximately half of CAH patients (21 of 40 with calcium measurements) had
persistent elevations of serum calcium across at least twomeasurements. Hypercalcemiawas
transient in most children and resolved over time without requiring specific intervention.
However, one patient remained hypercalcemic at the end the study period despite starting a
low-calcium diet. Our results suggest that children with CAH who are noted to have hy-
percalcemia are also at risk for developing hypercalciuria, nephrocalcinosis, and hyperten-
sion. Unfortunately, hypercalcemia on laboratory testing was frequently unrecognized and
most patients did not receive further testing for causes or complications of hypercalcemia.
Thus, the frequencies of hypercalciuria and nephrocalcinosis are uncertain because they may
have been undetected in some patients.
Patients with CAHhadmore hypercalcemia than the children between 0 and 5 years of age
undergoing laboratory testing in our children’s hospital (approximately 8.2% over a recent
1month time period). However, because healthy children do not routinely undergo laboratory
testing, this would not represent a true healthy control group.
The mechanism of hypercalcemia in AI is uncertain. Proposed mechanisms have included
increased bone resorption (though a bone biopsy study actually demonstrated low bone
turnover despite elevated bone resorption markers) [11]; increased gut absorption (which
some authors have suggested also does not explain the hypercalcemia in AI); or decreased
Table 2. Patients With Hypercalciuria and/or Nephrocalcinosis
Patient No.
1 2 3 4 5 6a 7a
Sex F M M M M F F
Highest Ca level,
mg/dLb
11.0 14.2 10.9 11.3 12.5 11.5 11.6
Mean Ca level, mg/dLb 10.2 12.2 10.3 10.1 10.4 10.5 10.3
Total no. of Ca
measurements
26 15 26 48 22 15 14
Ca range (min–max)b 9.5–11 10.6–14.2 9.2–10.9 9.5–11.3 9.5–12.5 9.7–11.5 9.8–11.6
Age at first elevated Ca
measurement, d
15 11 17 7 8 16 16
Age at last elevated Ca
measurement, mo
22 Unresolved at 5 0.3 1 1 26 21
Hypercalciuria Yes Yes Yes Yes No Yes Yes
Laboratory testing
performedc
Ca, mg/dLb 10 13.9 — — 11.2 10.6 10.4
Phos, mg/dLb 5.2 4.4 — — 9 — —
PTH, pg/mLb 25 ,1 — — — 31 46
25D, ng/mLb 29 43.9 — — — — —
1,25D, pg/mLb 69 58 — — — — —
Ur Ca/Cr 0.8 at 9 mo 2 at 5 mo 0.55 at 11 mo 0.83 at 2 mo 0.56 at 5 mod 0.73 at 2 y 0.81 at 2 y
Nephrocalcinosis No Yes No imaging Yes Yes No imaging No imaging
HTN No Yes No Yes Yes No No
Abbreviations: —, no data; 1,25D, calcitriol; 25D: calcidiol; Ca, calcium; HTN, hypertension; max, maximum; min,
minimum; Phos, phosphorus; PTH, parathyroid hormone; Ur Ca/Cr, urine calcium to creatinine ratio.
aPatients are twin sisters.
bConversion factors for SI units: Ca, multiply by 0.25 to get mmol/L; Phos, multiply by 0.323 to get mmol/L; PTH,
multiply by 1 to get ng/L; 25D, multiply by 2.496 to get nmol/L; 1,25D, multiply by 2.6 to get pmol/L.
cSerum samples drawn simultaneously, not at the time of hypercalcemia, for patients 1 and 7.
dPatient was treated for presumed hypercalciuria based on nephrocalcinosis and Ur Ca/Cr ratio.75th percentile for
age before treatment.
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glomerular filtration rate during adrenal crisis, leading to enhanced reabsorption of calcium
[8, 12–14]. Although AI may be a contributing factor for developing hypercalcemia, most
instances of elevated calcium levels occurred during glucocorticoid therapy. Interestingly,
serum calcium concentration was found to positively correlate with 17OHP concentration.
17OHP is often used as a marker of adrenal control in children with CAH. However, hy-
percalcemia was also noted to occur during both high and low 17OHP concentrations
(sometimes in the same patient), suggesting that perhaps mechanisms other than AI are also
involved. Our finding that higher doses of glucocorticoid were also associated with higher
calcium concentrations is unexpected, though this might be reflective of higher doses pre-
scribed in the setting of acute adrenal crisis or medication noncompliance.
Hypercalcemia in childrenwith CAHhas been anecdotally recognized, but to date, only one
other retrospective study, to our knowledge, has described hypercalcemia in two childrenwith
CAH [2]. This study of.61,000 childrenwas conducted to determine the frequency and causes
of childhood hypercalcemia. The authors reported hypercalcemia in only 203 children (0.33%)
with an overall frequency of sustained hypercalcemia (on two or more measurements) of one
per 500 children. Two of these cases of sustained hypercalcemia occurred in children with
CAH and were attributed to AI [2].
Interestingly, in our study, hypercalcemia associated with CAH appeared to occur primarily
in infancy and toddlerhood. This observation is consistent with the previous finding that 66% of
all sustained hypercalcemia occurred in children ,1 year of age vs 13.7% in children ages 1 to
5 years and 7.6% inadolescents [2]. In addition, childrenwithCAHhave themost admissions for
medical problems, including adrenal crisis, during the first year of life [15]. Consequently,
infants and young childrenwithCAHmaybe at greater risk for hypercalcemia. Thismay be due,
in part, to increaseddifficulties duringphlebotomy in children, resulting inprolonged tourniquet
time. Prolonged tourniquet time has been shown in other studies to cause mild hypercalcemia
due to artifact from hemoconcentration [16, 17]. This may be the reason some laboratories
generate slightly higher normal ranges for serum calcium in very young children. Although this
effect might explain some of the mild hypercalcemia seen in our study, two-thirds of the hy-
percalcemic patients had at least one serum calciummeasurement$11mg/dL ($2.75mmol/L).
Mechanisms for hypercalciuria and nephrocalcinosis in CAH are also unclear because AI
has not been reported to be a specific cause of renal pathology. It is possible that excessive salt
intake or mineralocorticoid treatment may play a role. High dietary salt ingestion has been
found to be associated with hypercalciuria and stone formation [18–21]. Calcium handling is
highly dependent on sodium in the renal proximal tubule. When presented with a salt load,
the reabsorption of sodium is diminished, aswell as that of calcium,which is passively coupled
with sodium and water [18]. It has been estimated that for every 100 mEq/dL increment of
sodium excretion in the urine, there is a 40 mg/dL rise in calcium excretion [22].
Sodium chloride supplementation is part of the standard therapy for children with classic
CAH and salt wasting, with a recommended total dose of 17 to 34 mEq/d divided throughout
the day [1]. Interestingly, one patient in our study who developed hypercalciuria had simple
virilizing CAH and was never treated with sodium chloride (but was receiving flu-
drocortisone). Doses of sodium chloride in the remaining five patients with hypercalciuria in
our study were within the recommended range for all but one patient, who was recorded as
taking 15mEq four times daily (60mEq/d). However, it is possible that this dose was recorded
incorrectly in the chart, because it is far outside the range of what is typically prescribed.
Although excessive salt load could explain hypercalciuria in these patients with CAH, it does
not explain hypercalcemia. An alternate explanation would be that the hypercalciuriamay be
secondary to hypercalcemia and an increased filtered load of serum calcium.
Nephrocalcinosis refers to calcium deposits in the tubules, tubular epithelium, and/or the
interstitial tissue of the kidney, and can result in deterioration of renal function [23]. The
biggest known risk factor for developing nephrocalcinosis is hypercalciuria. Of the three
patients in our study who had nephrocalcinosis, two had confirmed hypercalciuria with a
urine calcium to creatinine ratio.95th percentile for age and one patient had a high-normal
urine calcium to creatinine ratio (.75th percentile for age).
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Although hypercalciuria likely contributes to the development of nephrocalcinosis in
children with CAH, excess mineralocorticoid supplementation might also play a role. There
are three case reports of nephrocalcinosis thought to be due to hyperaldosteronism in young
men (ages 15, 17, and 22 years) with CAHdue to 11b-hydroxylase deficiency [22, 24]. All three
cases were undiagnosed in childhood and presented with significant hypertension and hy-
pokalemia. Likewise, nephrocalcinosis and renal cysts have been reported in the setting
of apparent mineralocorticoid excess syndrome, which is caused by 11b-hydroxysteroid
dehydrogenase deficiency in the kidney [25]. The pathogenesis of nephrocalcinosis due
to hyperaldosteronism is unclear; however, chronic hypokalemia resulting in ammonia-
mediated renal scarring has been postulated as a prime causal factor [22, 25]. None of the
patients in our study were noted to have long-standing hypokalemia and the three who
developed nephrocalcinosis were all prescribed fludrocortisone within the recommended dose
range of 0.05 to 0.2mg/d [1]. However, two of these patients did require higher fludrocortisone
doses in infancy (up to 0.3 mg/d and 0.4 mg/d) to maintain normal sodium, potassium, and
renin concentration, though this was ultimately weaned down to the standard range. Of note,
it is not uncommon for infants with CAH to require higher doses of fludrocortisone in infancy;
approximately 30% of the patients in this study were taking doses.0.2 mg daily. In addition,
anti-inflammatory doses of glucocorticoids have also been associated with the development of
nephrocalcinosis, whichmay be due to increasing the urine calcium and phosphorus excretion
[26–28]. However, again, these explanations do not account for the increased serum calcium
observed in our study.
There are a number of limitations to our retrospective study, particularly that only a
relatively small cohort of patients met our inclusion criteria. A large number of patients were
excluded owing to missing data or lack of calcium data. Similarly, few patients had renal
imaging or urine studies performed as part of their clinical evaluation. There are also several
confounding factors at play that cannot be controlled for in a retrospective study, such as
patient compliance with medication. Patients had laboratory data from laboratories all over
the state adding laboratory variability, thus our definition of .10.5 mg/dL may have over-
estimated or underestimated the true frequency of hypercalcemia.
5. Conclusion
This study demonstrates that hypercalcemia is a common finding in young children with
classic CAH and may place children at risk for serious renal complications such as hyper-
calciuria and nephrocalcinosis. Calcium monitoring during routine CAH laboratory testing
may beworthwhile in childrenwith CAH, particularly during the first year of life. Recognition
of hypercalcemia should be followed by appropriate evaluation to determine etiology and to
detect possible hypercalciuria and nephrocalcinosis. Further studies are needed to determine
the broader prevalence, etiology, and consequences of hypercalcemia in CAH.
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